Molecular classification and therapeutics in diffuse large B-cell lymphoma

Molecular classification and therapeutics in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) encompasses a wide variety of disease states that have to date been subgrouped and characterized based on immunohistochemical methods, which provide limited prognostic value to clinicians and no alteration in treatment regimen. The addition of rituximab to CHOP...

Full description

Bibliographic Details
Main Authors:	Gaelen Shimkus, Taichiro Nonaka
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Molecular Biosciences
Subjects:	DLBCL molecular diagnostics molecular classification signaling pathway targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fmolb.2023.1124360/full

Similar Items

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications
by: Georg Lenz
Published: (2015-05-01)

Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry
by: Rebekka Reber, et al.
Published: (2013-04-01)

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
by: Johanna Vets, et al.
Published: (2023-04-01)

Correlation between Germinal Center Differentiation and Double/Triple Hit Score in the Classification of Diffuse Large B Cell Non-Hodgkin Lymphoma: A Clinicopathological Approach
by: Israa Sobhy Abdel Razek Okap, et al.
Published: (2023-05-01)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
by: Xuemei Wu, et al.
Published: (2023-05-01)

Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy
by: Laura Tomas-Roca, et al.
Published: (2021-05-01)

Primary diffuse large B-cell lymphoma at gastrojejunostomy site: A rare case report
by: Shruthi, et al.
Published: (2023-01-01)

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?
by: Nicoletta Coccaro, et al.
Published: (2020-01-01)

Circulating miRNAs as biomarkers for the diagnosis in patients with melanoma: systematic review and meta-analysis
by: Nicholas Jones, et al.
Published: (2024-02-01)

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
by: Ryohei Kozaki, et al.
Published: (2018-04-01)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
by: Abdulhaq H, et al.
Published: (2023-07-01)

Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
by: Kirsten Thobe, et al.
Published: (2021-11-01)

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma
by: Changying Wang, et al.
Published: (2023-03-01)

BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
by: Weibo Kong, et al.
Published: (2021-11-01)

Salivary miRNAs as auxiliary liquid biopsy biomarkers for diagnosis in patients with oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis
by: Huy Nguyen, et al.
Published: (2024-03-01)

Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma - De Novo Occurrence or Transformation
by: Smeeta Gejendra, et al.
Published: (2015-11-01)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)

Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma
by: Kasper Thystrup Karstensen, et al.
Published: (2020-12-01)

Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction
by: Wenqi Wu, et al.
Published: (2023-01-01)

Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma
by: Aya Nakaya, et al.
Published: (2016-01-01)

The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
by: Matias Mendeville, et al.
Published: (2022-10-01)

Corrigendum: Identification of microtube-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction
by: Wenqi Wu, et al.
Published: (2023-06-01)

The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS
by: Ji-Wei Li, et al.
Published: (2024-01-01)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
by: Yazeed Sawalha
Published: (2021-12-01)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
by: Sicong Wang, et al.
Published: (2023-02-01)

CD30 Expression and Its Correlation with Clinicopathologic Features in Indonesian Diffuse Large B-Cell Lymphoma
by: Maria Reynelda Santoso, et al.
Published: (2020-09-01)

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma
by: Leila Mohammadnezhad, et al.
Published: (2023-05-01)

Inflammatory Cells in Diffuse Large B Cell Lymphoma
by: Roberto Tamma, et al.
Published: (2020-07-01)

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
by: Mark J. Bishton, et al.
Published: (2023-02-01)

The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B‐cell lymphoma
by: Haixiang Pei, et al.
Published: (2022-06-01)

Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma
by: Cheng-Han Wu, et al.
Published: (2022-04-01)

Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (<i>Procyon lotor</i>)
by: Giulia D’Annunzio, et al.
Published: (2022-11-01)

An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma
by: Fenling Zhou, et al.
Published: (2023-07-01)

Utility of reverse transcriptase – Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO)
by: Nicholas Dcunha, et al.
Published: (2023-01-01)

Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma
by: Sara Petronilho, et al.
Published: (2021-12-01)

The IL‐6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B‐cell lymphoma
by: Hind Hashwah, et al.
Published: (2019-10-01)

STATUS ANEMIA TIDAK BERHUBUNGAN DENGAN SUBTIPE DIFFUSE LARGE B-CELL LYMPHOMA
by: Angga Febriyanto, et al.
Published: (2023-12-01)

Profiling risk factors for separation of infection complications in patients with gastrointestinal and nodal diffuse large B-cell lymphoma
by: Min Xue, et al.
Published: (2023-10-01)

R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma
by: Mishima Yuko, et al.
Published: (2012-09-01)

Gastrosplenic fistula due to diffuse large B-cell lymphoma: case report
by: Ahmed Elsahhar, et al.
Published: (2024-02-01)